BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.9250
+0.1250 (+4.46%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.8000
Open2.8000
Bid2.8000 x 41800
Ask0.0000 x 21500
Day's Range2.8000 - 3.0800
52 Week Range1.3800 - 9.2600
Volume4,120,736
Avg. Volume3,516,583
Market Cap450.623M
Beta (5Y Monthly)2.13
PE Ratio (TTM)N/A
EPS (TTM)-1.2130
Earnings DateMar 01, 2020 - Mar 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.13
  • GlobeNewswire

    FDA Accepts BioCryst’s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks

    BioCryst Pharmaceuticals, Inc. (BCRX) announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its new drug application (NDA) for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks. The Prescription Drug User Fee Act (PDUFA) date for the NDA is December 3, 2020. In the NDA filing acceptance letter, the FDA stated that they are not currently planning to hold an advisory committee meeting to discuss the NDA.

  • How Many BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Did Insiders Buy, In The Last Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • GlobeNewswire

    BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees options to purchase an aggregate of 140,000 shares of BioCryst common stock on January 31, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $2.85 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date.

  • Steven Cohen Renews His Interest in Verastem
    GuruFocus.com

    Steven Cohen Renews His Interest in Verastem

    Guru invests in restructuring cancer drug developer Continue reading...

  • GlobeNewswire

    BioCryst Submits Japanese New Drug Application for Oral, Once Daily Berotralstat

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced that it has submitted a new drug application (JNDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for approval of oral, once daily berotralstat for the prophylactic treatment of hereditary angioedema (HAE). “The data from APeX-J and the berotralstat clinical program are very exciting for HAE patients in Japan,” said Dr. Isao Ohsawa, president of Saiyu Soka hospital and principal investigator of the APeX-J trial. “Based on the clinical benefit observed in patients in APeX-J, I expect many patients in Japan will want to use this new treatment, once it becomes available,” he added.

  • Benzinga

    13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak

    Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.

  • GlobeNewswire

    BioCryst Strengthens Commercial Rare Disease Leadership

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced the appointments of Charles Gayer as chief commercial officer and Allen Hodge as vice president and general manager for the United States. Mr. Gayer joined BioCryst in 2015 as vice president of global strategic marketing. Since July 2019 he has served as interim chief commercial officer, playing a key role in defining the strategy, and building the commercial operations, to support the launch of berotralstat, BioCryst’s oral kallikrein inhibitor for hereditary angioedema (HAE).

  • Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
    Zacks

    Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?

    Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

  • GlobeNewswire

    BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees options to purchase an aggregate of 20,000 shares of BioCryst common stock on December 31, 2019 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $3.45 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date.

  • GlobeNewswire

    BioCryst to Present at 38th Annual J.P. Morgan Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2020 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 38th Annual J.P. Morgan.

  • The ups and downs for stocks of Triangle drugmakers in 2019
    American City Business Journals

    The ups and downs for stocks of Triangle drugmakers in 2019

    Despite a strong economy and promising therapeutic candidates, many public companies in the Triangle's life sciences sector saw a difficult year in terms of their stock price while other companies made large exits and rebounds.

  • BioCryst Submits NDA for Hereditary Angioedema Candidate
    Zacks

    BioCryst Submits NDA for Hereditary Angioedema Candidate

    BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.

  • BioCryst seeks federal approval for its lead drug candidate
    American City Business Journals

    BioCryst seeks federal approval for its lead drug candidate

    A Triangle-drugmaker long-engaged in locking down funding for its lead candidate has officially filed for approval of its drug – kicking off the beginning of an anticipated commercialization process begging in 2020.

  • Here is What Hedge Funds Think About BioCryst Pharmaceuticals, Inc. (BCRX)
    Insider Monkey

    Here is What Hedge Funds Think About BioCryst Pharmaceuticals, Inc. (BCRX)

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

  • GlobeNewswire

    BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks

    BioCryst Pharmaceuticals, Inc. (BCRX) announced it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks. “HAE patients are waiting for a safe, effective oral therapy to manage their disease and this NDA submission brings berotralstat an important step closer to meeting this need for patients and their physicians,” said Jon Stonehouse, chief executive officer of BioCryst.

  • Implied Volatility Surging for BioCryst (BCRX) Stock Options
    Zacks

    Implied Volatility Surging for BioCryst (BCRX) Stock Options

    Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

  • GlobeNewswire

    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees options to purchase an aggregate of 142,500 shares of BioCryst common stock on November 29, 2019 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $2.85 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date.

  • Thomson Reuters StreetEvents

    Edited Transcript of BCRX earnings conference call or presentation 6-Nov-19 1:00pm GMT

    Q3 2019 BioCryst Pharmaceuticals Inc Earnings Call and Update on the Commercial Opportunity

  • BioCryst locks down another $20M on heels of public offering
    American City Business Journals

    BioCryst locks down another $20M on heels of public offering

    A Triangle drugmaker continues to pile up funding in an end-of-year blitz ahead of its anticipated commercial roll-out.

  • GlobeNewswire

    BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

    BioCryst Pharmaceuticals, Inc. (BCRX) announced today the completion of an underwritten public offering of 43,620,690 shares of its common stock, including 5,689,655 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from this offering to BioCryst, including from the shares sold pursuant to the underwriters’ option to purchase additional shares, were approximately $63.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BioCryst. BioCryst expects to use the net proceeds of this offering for general corporate purposes, which may include, but are not limited to, worldwide development, manufacturing, regulatory and commercial activities for the prophylactic BCX7353 program, primarily focusing on the U.S., EU and Japan; development of the BCX9930 program; development of the BCX9250 program; post-approval commitments for RAPIVAB®/ALPIVABTM; funding clinical development of pipeline assets; and capital expenditures and other general corporate expenses.

  • Benzinga

    Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially

    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) completed a $55 million equity raise earlier this week. Doctor checks conducted after the release of pivotal ApeX-2 study results in hereditary angioedema (HAE) had indicated interest in BioCryst Pharma’s ‘7353, given the convenience of its oral dosing, Ahmad said in the upgrade note. The New Drug Application (NDA) filing of ‘7353 in prophylactic HAE with the European Union this quarter and Japan submission in the first quarter of 2020 are likely to be key near-term catalysts for the stock, Ahmad said.

  • Benzinga

    The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

  • GlobeNewswire

    BioCryst to Present at Upcoming Investor Conferences

    RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies London Healthcare.

  • Durham company sets stage for $55 million offering
    American City Business Journals

    Durham company sets stage for $55 million offering

    Just ahead of the anticipated roll-out of its main drug, a Triangle company is going out to market with a $55 million offering.

  • GlobeNewswire

    BioCryst Prices Public Offering of Common Stock

    The gross proceeds from this offering to BioCryst are expected to be $55 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioCryst. BioCryst has granted the underwriters a 30-day option to purchase up to an additional 5,689,655 shares of its common stock. BioCryst expects to use the net proceeds of this offering for general corporate purposes, which may include, but are not limited to, worldwide development, manufacturing, regulatory and commercial activities for the prophylactic BCX7353 program, primarily focusing on the U.S., EU and Japan; development of the BCX9930 program; development of the BCX9250 program; post-approval commitments for RAPIVAB®/ALPIVAB™; funding clinical development of pipeline assets; and capital expenditures and other general corporate expenses.